These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 2900190

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The sensitivity of growth hormone and prolactin secretion to the somatostatin analogue SMS 201-995 in patients with prolactinomas and acromegaly.
    Lamberts SW, Zweens M, Klijn JG, van Vroonhoven CC, Stefanko SZ, Del Pozo E.
    Clin Endocrinol (Oxf); 1986 Aug; 25(2):201-12. PubMed ID: 2878748
    [Abstract] [Full Text] [Related]

  • 3. Treatment of acromegaly with the long-acting somatostatin analog SMS 201-995.
    Barkan AL, Kelch RP, Hopwood NJ, Beitins IZ.
    J Clin Endocrinol Metab; 1988 Jan; 66(1):16-23. PubMed ID: 2891720
    [Abstract] [Full Text] [Related]

  • 4. Medical treatment of acromegaly with SMS 201-995, a somatostatin analog: a comparison with bromocriptine.
    Chiodini PG, Cozzi R, Dallabonzana D, Oppizzi G, Verde G, Petroncini M, Liuzzi A, del Pozo E.
    J Clin Endocrinol Metab; 1987 Mar; 64(3):447-53. PubMed ID: 2880861
    [Abstract] [Full Text] [Related]

  • 5. Relationship between somatomedin-C and growth hormone levels in acromegaly: basal and dynamic evaluation.
    Oppizzi G, Petroncini MM, Dallabonzana D, Cozzi R, Verde G, Chiodini PG, Liuzzi A.
    J Clin Endocrinol Metab; 1986 Dec; 63(6):1348-53. PubMed ID: 2878007
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Acromegaly from ectopic growth hormone-releasing hormone secretion by a malignant carcinoid tumor. Successful treatment with long-acting somatostatin analogue SMS 201-995.
    Barkan AL, Shenker Y, Grekin RJ, Vale WW.
    Cancer; 1988 Jan 15; 61(2):221-6. PubMed ID: 2891432
    [Abstract] [Full Text] [Related]

  • 11. Long-term treatment of acromegaly with Sandostatin (SMS 201-995). Normalization of most anomalous growth hormone responses.
    Pieters GF, van Liessum PA, Smals AG, van Gennep JA, Benraad TJ, Kloppenborg PW.
    Acta Endocrinol Suppl (Copenh); 1987 Jan 15; 286():9-18. PubMed ID: 2892339
    [Abstract] [Full Text] [Related]

  • 12. The effect of the somatostatin analog SMS 201-995 on normal growth hormone secretion in the rat. A comparison with the effect of bromocriptine on normal prolactin secretion.
    Lamberts SW, Verleun T, Zuiderwijk JM, Oosterom R.
    Acta Endocrinol (Copenh); 1987 Jun 15; 115(2):196-202. PubMed ID: 2885995
    [Abstract] [Full Text] [Related]

  • 13. Desensitization to somatostatin analogue (Octreotide) observed in a patient with acromegaly.
    Haraguchi K, Ohtaka M, Takazawa K, Endo T, Onaya T.
    Endocr J; 1995 Apr 15; 42(2):295-300. PubMed ID: 7627275
    [Abstract] [Full Text] [Related]

  • 14. Acute and long-term effects of SMS 201-995 in acromegaly.
    Lamberts SW, del Pozo E.
    Scand J Gastroenterol Suppl; 1986 Apr 15; 119():141-8. PubMed ID: 2876498
    [Abstract] [Full Text] [Related]

  • 15. [Novel pharmacologic therapies in acromegaly].
    Góth M, Hubina E, Kovács L, Szabolcs I.
    Orv Hetil; 2002 May 12; 143(19 Suppl):1057-62. PubMed ID: 12063860
    [Abstract] [Full Text] [Related]

  • 16. The sensitivity of growth hormone secretion to medical treatment in acromegalic patients: influence of age and sex.
    van der Lely AJ, Harris AG, Lamberts SW.
    Clin Endocrinol (Oxf); 1992 Aug 12; 37(2):181-5. PubMed ID: 1395069
    [Abstract] [Full Text] [Related]

  • 17. Comparison of the effectiveness of 2-hourly versus 8-hourly subcutaneous injections of a somatostatin analog (SMS 201-995) in the treatment of acromegaly.
    Wang C, Lam KS, Arceo E, Chan FL.
    J Clin Endocrinol Metab; 1989 Sep 12; 69(3):670-7. PubMed ID: 2668325
    [Abstract] [Full Text] [Related]

  • 18. Bromocriptine, a dopamine agonist, increases growth hormone secretion in a patient with acromegaly.
    Arihara Z, Sakurai K, Yamashita R, Niitsuma S, Ueno T, Yamamura N, Yamada S, Inoshita N, Takahashi K.
    Tohoku J Exp Med; 2014 Oct 12; 234(2):129-35. PubMed ID: 25253414
    [Abstract] [Full Text] [Related]

  • 19. A comparison between the effects of SMS 201-995, bromocriptine and a combination of both drugs on hormone release by the cultured pituitary tumour cells of acromegalic patients.
    Lamberts SW, Verleun T, Hofland L, Del Pozo E.
    Clin Endocrinol (Oxf); 1987 Jul 12; 27(1):11-23. PubMed ID: 2888550
    [Abstract] [Full Text] [Related]

  • 20. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.
    Quabbe HJ, Plöckinger U.
    J Clin Endocrinol Metab; 1989 May 12; 68(5):873-81. PubMed ID: 2565912
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.